Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. 2009

Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
Toronto Western Research Institute, 399 Bathurst Street, MC11-419, Toronto, Ontario M5T 2S8, Canada.

Development of L-DOPA-induced dyskinesia (LID) remains a major problem in the long-term treatment of Parkinson's disease (PD). Sensitization to L-DOPA correlates with ectopic expression of D3 dopamine receptors in the striatum, implicating D3 receptors in development of LID. We demonstrate that the selective D3 antagonist S33084 abolishes development of LID over 30 days in MPTP-lesioned marmosets without effecting the anti-parkinsonian actions of L-DOPA. Furthermore, following a 14 day washout, when challenged with L-DOPA in the absence of S33084, these animals continued to exhibit reduced LID. In the 6-OHDA-lesioned rat, S33084 similarly attenuated development of behavioural sensitization to L-DOPA. Additionally, L-DOPA-induced elevations in striatal pre-proenkephalin-A (PPE-A) (but not PPE-B, phospho[Thr(34)]DARPP-32, D1, and D2 receptor mRNA or D3 receptor levels) were reduced in S33084 treated animals. Our data suggest a role for D3 receptors in the development of LID and suggest that initiating L-DOPA treatment with a D3 antagonist may reduce the development of LID in PD.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D011498 Protein Precursors Precursors, Protein
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D002144 Callithrix A genus of the subfamily CALLITRICHINAE occurring in forests of Brazil and Bolivia and containing seventeen species. Callithrix jacchus,Hapale,Marmoset, Common,Marmoset, Short-Tusked,Marmosets,Common Marmoset,Common Marmosets,Marmoset,Marmoset, Short Tusked,Short-Tusked Marmoset,Short-Tusked Marmosets
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D004745 Enkephalins One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. Enkephalin
D005260 Female Females

Related Publications

Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
March 2021, Biomedicines,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
July 2018, Movement disorders : official journal of the Movement Disorder Society,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
January 2014, PloS one,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
January 2017, International journal of molecular sciences,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
December 2013, CNS & neurological disorders drug targets,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
January 2015, Bulletin de l'Academie nationale de medecine,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
July 2015, Neuroscience,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
January 2017, Cerebral cortex (New York, N.Y. : 1991),
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
February 2021, Experimental neurology,
Naomi P Visanji, and Susan H Fox, and Tom Johnston, and Gabriela Reyes, and Mark J Millan, and Jonathan M Brotchie
August 2008, Psychopharmacology,
Copied contents to your clipboard!